Patients with Chronic Lymphocytic Leukemia (CLL), a type of blood cancer, may be prone to infections due to low antibodies levels. This vulnerability stems from the very nature of some hematological malignancies, characterized by the cancer infiltrating the bone marrow and suppressing the production of B cells – the body’s antibodies producer. Consequently, these patients not only grapple with CLL, but also carry an amplified risk of infections arising from secondary hypogammaglobulinemia. To counteract these infections, healthcare providers typically resort to immunoglobulin (Ig) replacement therapy or preventative antibiotics. However, until recently, a direct comparison of their efficacy was absent.
In order to address this gap, Professor Zoe McQuilten of Monash Health, Australia, in collaboration with her counterparts in seven hospitals across Australia and New Zealand, embarked on a study. The researchers primarily focused on patients with a history of severe or recurrent infections or exceedingly low levels of immunoglobulin G, less than 4 g/L.
The study randomly distributed these patients into two categories. One group received immunoglobulin replacement therapy every four weeks intravenously, while the other was administered daily preventative antibiotics trimethoprim-sulfamethoxazole or doxycycline for 12 months. By the study’s conclusion at the one-year mark, 76% of those who were under the immunoglobulin therapy were still alive compared to 71% of the patients who were under the antibiotic regimen. Both groups saw a similar timeframe until the occurrence of the first major infection and reported similar quality of life throughout the treatment duration.
Interestingly, contrary to earlier trials that linked immunoglobulin replacement with a reduced risk of clinically documented infections but not mortality, this trail suggests that both antibiotics and immunoglobulin replacement therapy may be on equal footing in preventing infections under the tested conditions. The researchers’ groundbreaking work has shed light on the comparative effectiveness of these infection prevention measures, thereby paving the way for more detailed evaluations in the future. These findings could play a pivotal role in fine-tuning infection prevention strategies for patients with CLL.
Megan Heaps, who joined HealthTree in 2022 and the daughter of a blood cancer patient, has a deep personal commitment to enhancing patients’ understanding of their disease. Such understanding equips patients and their caregivers to advocate more effectively for themselves, ultimately improving their treatment outcomes.
Source: https://healthtree.org/cll/community/articles/immunoglobulin-vs-antibiotics-for-cll-infections